{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T18:23:03Z","timestamp":1792693383989,"version":"4.5.0"},"reference-count":77,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,4,15]],"date-time":"2021-04-15T00:00:00Z","timestamp":1618444800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,4,15]],"date-time":"2021-04-15T00:00:00Z","timestamp":1618444800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001602","name":"Science Foundation Ireland","doi-asserted-by":"publisher","award":["11\/Y\/B2093"],"award-info":[{"award-number":["11\/Y\/B2093"]}],"id":[{"id":"10.13039\/501100001602","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001602","name":"Science Foundation Ireland","doi-asserted-by":"publisher","award":["11\/Y\/B2093"],"award-info":[{"award-number":["11\/Y\/B2093"]}],"id":[{"id":"10.13039\/501100001602","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004162","name":"Meath Foundation","doi-asserted-by":"publisher","award":["208591"],"award-info":[{"award-number":["208591"]}],"id":[{"id":"10.13039\/501100004162","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004162","name":"Meath Foundation","doi-asserted-by":"publisher","award":["208591"],"award-info":[{"award-number":["208591"]}],"id":[{"id":"10.13039\/501100004162","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004162","name":"Meath Foundation","doi-asserted-by":"publisher","award":["208591"],"award-info":[{"award-number":["208591"]}],"id":[{"id":"10.13039\/501100004162","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Type I interferon (IFN) dysregulation is a major contributory factor in the development of several autoimmune diseases, termed type I interferonopathies, and is thought to be the pathogenic link with chronic inflammation in these conditions. Anti-neutrophil cytoplasmic antibody (ANCA)-Associated Vasculitis (AAV) is an autoimmune disease characterised by necrotising inflammation of small blood vessels. The underlying biology of AAV is not well understood, however several studies have noted abnormalities in type I IFN responses. We hypothesised that type I IFN responses are systemically dysregulated in AAV, consistent with features of a type I interferonopathy. To investigate this, we measured the expression of seven interferon regulated genes (IRGs) (<jats:italic>ISG15, SIGLEC1, STAT1, RSAD2, IFI27, IFI44L<\/jats:italic>and<jats:italic>IFIT1<\/jats:italic>) in peripheral blood samples, as well as three type I IFN regulated proteins (CXCL10, MCP-1 and CCL19) in serum samples from AAV patients, healthy controls and disease controls. We found no difference in type I IFN regulated gene or protein expression between AAV patients and healthy controls. Furthermore, IRG and IFN regulated protein expression did not correlate with clinical measurements of disease activity in AAV patients. Thus, we conclude that systemic type I IFN responses are not key drivers of AAV pathogenesis and AAV should not be considered a type I interferonopathy.<\/jats:p>","DOI":"10.1038\/s41598-021-87760-4","type":"journal-article","created":{"date-parts":[[2021,4,15]],"date-time":"2021-04-15T10:18:05Z","timestamp":1618481885000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Investigation of type I interferon responses in ANCA-associated vasculitis"],"prefix":"10.1038","volume":"11","author":[{"given":"Isabella","family":"Batten","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark W.","family":"Robinson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arthur","family":"White","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cathal","family":"Walsh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Fazekas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason","family":"Wyse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonia","family":"Buettner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suzanne","family":"D\u2019Arcy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily","family":"Greenan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Conor C.","family":"Murphy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zoe","family":"Wigston","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joan N\u00ed","family":"Gabhann-Dromgoole","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward M.","family":"Vital","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark A.","family":"Little","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nollaig M.","family":"Bourke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,4,15]]},"reference":[{"issue":"1","key":"87760_CR1","doi-asserted-by":"publisher","first-page":"3268","DOI":"10.1038\/s41598-018-20203-9","volume":"8","author":"KL Connelly","year":"2018","unstructured":"Connelly, K. L. et al. Longitudinal association of type 1 interferon-induced chemokines with disease activity in systemic lupus erythematosus. Sci. Rep. 8(1), 3268 (2018).","journal-title":"Sci. Rep."},{"issue":"12","key":"87760_CR2","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.1016\/S1474-4422(13)70258-8","volume":"12","author":"GI Rice","year":"2013","unstructured":"Rice, G. I. et al. Assessment of interferon-related biomarkers in Aicardi-Gouti\u00e8res syndrome associated with mutations in TREX1, RNASEH2A, RNASEH2B, RNASEH2C, SAMHD1, and ADAR: a case-control study. Lancet Neurol. 12(12), 1159\u20131169 (2013).","journal-title":"Lancet Neurol."},{"key":"87760_CR3","doi-asserted-by":"publisher","first-page":"2061","DOI":"10.3389\/fimmu.2018.02061","volume":"9","author":"AJ Lee","year":"2018","unstructured":"Lee, A. J. & Ashkar, A. A. The dual nature of type I and type II interferons. Front. Immunol. 9, 2061 (2018).","journal-title":"Front. Immunol."},{"issue":"3","key":"87760_CR4","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1016\/j.it.2015.02.002","volume":"36","author":"RA Porritt","year":"2015","unstructured":"Porritt, R. A. & Hertzog, P. J. Dynamic control of type I IFN signalling by an integrated network of negative regulators. Trends Immunol. 36(3), 150\u2013160 (2015).","journal-title":"Trends Immunol."},{"key":"87760_CR5","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1111\/j.1749-6632.2011.06220.x","volume":"1238","author":"YJ Crow","year":"2011","unstructured":"Crow, Y. J. Type I interferonopathies: a novel set of inborn errors of immunity. Ann. N. Y. Acad. Sci. 1238, 91\u201398 (2011).","journal-title":"Ann. N. Y. Acad. Sci."},{"issue":"1\u20132","key":"87760_CR6","doi-asserted-by":"publisher","first-page":"59","DOI":"10.2119\/2006-00085.Baechler","volume":"13","author":"EC Baechler","year":"2007","unstructured":"Baechler, E. C. et al. An interferon signature in the peripheral blood of dermatomyositis patients is associated with disease activity. Mol. Med. 13(1\u20132), 59\u201368 (2007).","journal-title":"Mol. Med."},{"issue":"2","key":"87760_CR7","doi-asserted-by":"publisher","first-page":"310","DOI":"10.3899\/jrheum.100486","volume":"38","author":"O Kimoto","year":"2011","unstructured":"Kimoto, O. et al. Activation of the interferon pathway in peripheral blood of patients with Sjogren\u2019s syndrome. J. Rheumatol. 38(2), 310\u2013316 (2011).","journal-title":"J. Rheumatol."},{"issue":"12","key":"87760_CR8","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1007\/s11926-013-0383-6","volume":"15","author":"I Khan","year":"2013","unstructured":"Khan, I. & Watts, R. A. Classification of ANCA-associated vasculitis. Curr. Rheumatol. Rep. 15(12), 383 (2013).","journal-title":"Curr. Rheumatol. Rep."},{"issue":"9","key":"87760_CR9","doi-asserted-by":"publisher","first-page":"1656","DOI":"10.1093\/rheumatology\/kew232","volume":"55","author":"FA Pearce","year":"2016","unstructured":"Pearce, F. A. et al. Incidence of ANCA-associated vasculitis in a UK mixed ethnicity population. Rheumatology (Oxford) 55(9), 1656\u20131663 (2016).","journal-title":"Rheumatology (Oxford)"},{"issue":"12","key":"87760_CR10","doi-asserted-by":"publisher","first-page":"2338","DOI":"10.1002\/art.40313","volume":"69","author":"A Berti","year":"2017","unstructured":"Berti, A. et al. The epidemiology of antineutrophil cytoplasmic autoantibody-associated vasculitis in Olmsted County, Minnesota: a twenty-year US population-based study. Arthritis Rheumatol. 69(12), 2338\u20132350 (2017).","journal-title":"Arthritis Rheumatol."},{"issue":"8","key":"87760_CR11","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1002\/art.1780330802","volume":"33","author":"GG Hunder","year":"1990","unstructured":"Hunder, G. G. et al. The American College of Rheumatology 1990 criteria for the classification of vasculitis. Introduction.. Arthritis Rheum. 33(8), 1065\u20131067 (1990).","journal-title":"Arthritis Rheum."},{"key":"87760_CR12","unstructured":"Robbins, S. L. & Cotran, R. S. Robbins and Cotran Pathologic Basis of Disease 7th edn, (eds Kumar, V., Abul, K. & Fausto, N.) 9 (Elsevier Saunders, 2005)."},{"key":"87760_CR13","doi-asserted-by":"publisher","first-page":"2603","DOI":"10.3389\/fimmu.2019.02603","volume":"10","author":"A Ui Mhaonaigh","year":"2019","unstructured":"Ui Mhaonaigh, A. et al. Low density granulocytes in ANCA vasculitis are heterogenous and hypo-responsive to anti-myeloperoxidase antibodies. Front. Immunol. 10, 2603 (2019).","journal-title":"Front. Immunol."},{"issue":"4","key":"87760_CR14","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1007\/s00281-014-0436-6","volume":"36","author":"EF McKinney","year":"2014","unstructured":"McKinney, E. F. et al. The immunopathology of ANCA-associated vasculitis. Semin. Immunopathol. 36(4), 461\u2013478 (2014).","journal-title":"Semin. Immunopathol."},{"key":"87760_CR15","doi-asserted-by":"publisher","first-page":"e26","DOI":"10.1136\/bmj.e26","volume":"344","author":"A Berden","year":"2012","unstructured":"Berden, A. et al. Diagnosis and management of ANCA associated vasculitis. BMJ 344, e26 (2012).","journal-title":"BMJ"},{"issue":"6","key":"87760_CR16","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1038\/nm.1959","volume":"15","author":"K Kessenbrock","year":"2009","unstructured":"Kessenbrock, K. et al. Netting neutrophils in autoimmune small-vessel vasculitis. Nat. Med. 15(6), 623\u2013625 (2009).","journal-title":"Nat. Med."},{"issue":"1","key":"87760_CR17","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1186\/s13075-017-1328-7","volume":"19","author":"A Ishizu","year":"2017","unstructured":"Ishizu, A. et al. Prediction of response to remission induction therapy by gene expression profiling of peripheral blood in Japanese patients with microscopic polyangiitis. Arthritis Res. Ther. 19(1), 117 (2017).","journal-title":"Arthritis Res. Ther."},{"key":"87760_CR18","first-page":"374312","volume":"2009","author":"Y Yao","year":"2009","unstructured":"Yao, Y. et al. Development of potential pharmacodynamic and diagnostic markers for anti-IFN-\u03b1 monoclonal antibody trials in systemic lupus erythematosus. Hum. Genomics Proteomics 2009, 374312 (2009).","journal-title":"Hum. Genomics Proteomics"},{"issue":"3","key":"87760_CR19","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1056\/NEJMoa1912196","volume":"382","author":"EF Morand","year":"2020","unstructured":"Morand, E. F. et al. Trial of anifrolumab in active systemic lupus erythematosus. N. Engl. J. Med. 382(3), 211\u2013221 (2020).","journal-title":"N. Engl. J. Med."},{"issue":"2","key":"87760_CR20","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1007\/s10875-016-0359-1","volume":"37","author":"GI Rice","year":"2017","unstructured":"Rice, G. I. et al. Assessment of type I interferon signaling in pediatric inflammatory disease. J. Clin. Immunol. 37(2), 123\u2013132 (2017).","journal-title":"J. Clin. Immunol."},{"issue":"1","key":"87760_CR21","doi-asserted-by":"publisher","first-page":"R23","DOI":"10.1186\/ar4451","volume":"16","author":"PR Dominguez-Gutierrez","year":"2014","unstructured":"Dominguez-Gutierrez, P. R. et al. Reduced levels of CCL2 and CXCL10 in systemic lupus erythematosus patients under treatment with prednisone, mycophenolate mofetil, or hydroxychloroquine, except in a high STAT1 subset. Arthritis Res. Ther. 16(1), R23 (2014).","journal-title":"Arthritis Res. Ther."},{"issue":"7344","key":"87760_CR22","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1038\/nature09907","volume":"472","author":"JW Schoggins","year":"2011","unstructured":"Schoggins, J. W. et al. A diverse range of gene products are effectors of the type I interferon antiviral response. Nature 472(7344), 481\u2013485 (2011).","journal-title":"Nature"},{"issue":"3","key":"87760_CR23","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1111\/j.1365-2249.2009.04057.x","volume":"159","author":"QZ Li","year":"2010","unstructured":"Li, Q. Z. et al. Interferon signature gene expression is correlated with autoantibody profiles in patients with incomplete lupus syndromes. Clin. Exp. Immunol. 159(3), 281\u2013291 (2010).","journal-title":"Clin. Exp. Immunol."},{"issue":"1","key":"87760_CR24","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1002\/jcp.20948","volume":"211","author":"C Yan","year":"2007","unstructured":"Yan, C. & Boyd, D. D. Regulation of matrix metalloproteinase gene expression. J. Cell Physiol. 211(1), 19\u201326 (2007).","journal-title":"J. Cell Physiol."},{"issue":"17","key":"87760_CR25","doi-asserted-by":"publisher","first-page":"11321","DOI":"10.1074\/jbc.272.17.11321","volume":"272","author":"B Perron","year":"1997","unstructured":"Perron, B. et al. Can enzymatic activity, or otherwise, be inferred from structural studies of annexin III?. J. Biol. Chem. 272(17), 11321\u201311326 (1997).","journal-title":"J. Biol. Chem."},{"issue":"7562","key":"87760_CR26","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1038\/nature14468","volume":"523","author":"EF McKinney","year":"2015","unstructured":"McKinney, E. F. et al. T-cell exhaustion, co-stimulation and clinical outcome in autoimmunity and infection. Nature 523(7562), 612\u2013616 (2015).","journal-title":"Nature"},{"issue":"3","key":"87760_CR27","doi-asserted-by":"publisher","first-page":"416","DOI":"10.2215\/CJN.07300712","volume":"8","author":"R Goupil","year":"2013","unstructured":"Goupil, R. et al. Lymphopenia and treatment-related infectious complications in ANCA-associated vasculitis. Clin. J. Am. Soc. Nephrol. 8(3), 416\u2013423 (2013).","journal-title":"Clin. J. Am. Soc. Nephrol."},{"issue":"1","key":"87760_CR28","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1186\/s12882-018-0992-4","volume":"19","author":"SS Ahn","year":"2018","unstructured":"Ahn, S. S. et al. Neutrophil to lymphocyte ratio at diagnosis can estimate vasculitis activity and poor prognosis in patients with ANCA-associated vasculitis: a retrospective study. BMC Nephrol. 19(1), 187 (2018).","journal-title":"BMC Nephrol."},{"key":"87760_CR29","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1080\/19768354.2016.1191544","volume":"20","author":"J Jung","year":"2016","unstructured":"Jung, J. & Jung, H. Methods to analyze cell type-specific gene expression profiles from heterogeneous cell populations. Anim. Cells Syst. 20, 113\u2013117 (2016).","journal-title":"Anim. Cells Syst."},{"key":"87760_CR30","doi-asserted-by":"publisher","first-page":"827","DOI":"10.3389\/fimmu.2020.00827","volume":"11","author":"B Diao","year":"2020","unstructured":"Diao, B. et al. Reduction and functional exhaustion of T cells in patients with coronavirus disease 2019 (COVID-19). Front. Immunol. 11, 827 (2020).","journal-title":"Front. Immunol."},{"issue":"2","key":"87760_CR31","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1136\/thorax.56.2.121","volume":"56","author":"UK Kolling","year":"2001","unstructured":"Kolling, U. K. et al. Leucocyte response and anti-inflammatory cytokines in community acquired pneumonia. Thorax 56(2), 121\u2013125 (2001).","journal-title":"Thorax"},{"issue":"5","key":"87760_CR32","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1016\/j.autrev.2012.10.006","volume":"12","author":"Y Yao","year":"2013","unstructured":"Yao, Y. et al. Type I interferons in Sj\u00f6gren\u2019s syndrome. Autoimmun. Rev. 12(5), 558\u2013566 (2013).","journal-title":"Autoimmun. Rev."},{"issue":"10","key":"87760_CR33","doi-asserted-by":"publisher","first-page":"3098","DOI":"10.1002\/art.24803","volume":"60","author":"JW Bauer","year":"2009","unstructured":"Bauer, J. W. et al. Interferon-regulated chemokines as biomarkers of systemic lupus erythematosus disease activity: a validation study. Arthritis Rheum. 60(10), 3098\u20133107 (2009).","journal-title":"Arthritis Rheum."},{"issue":"1","key":"87760_CR34","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/j.it.2017.07.001","volume":"39","author":"D Ganguly","year":"2018","unstructured":"Ganguly, D. Do type I interferons link systemic autoimmunities and metabolic syndrome in a pathogenetic continuum?. Trends Immunol. 39(1), 28\u201343 (2018).","journal-title":"Trends Immunol."},{"issue":"9","key":"87760_CR35","doi-asserted-by":"publisher","first-page":"2951","DOI":"10.1002\/art.22044","volume":"54","author":"X Feng","year":"2006","unstructured":"Feng, X. et al. Association of increased interferon-inducible gene expression with disease activity and lupus nephritis in patients with systemic lupus erythematosus. Arthritis Rheum. 54(9), 2951\u20132962 (2006).","journal-title":"Arthritis Rheum."},{"issue":"10","key":"87760_CR36","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1089\/jir.2014.0171","volume":"35","author":"K Edvardsen","year":"2015","unstructured":"Edvardsen, K. et al. Peripheral blood cells from patients with autoimmune Addison\u2019s disease poorly respond to interferons in vitro, despite elevated serum levels of interferon-inducible chemokines. J. Interferon Cytokine Res. 35(10), 759\u2013770 (2015).","journal-title":"J. Interferon Cytokine Res."},{"issue":"1","key":"87760_CR37","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.mce.2012.09.004","volume":"365","author":"E Bratland","year":"2013","unstructured":"Bratland, E., Hellesen, A. & Husebye, E. S. Induction of CXCL10 chemokine in adrenocortical cells by stimulation through toll-like receptor 3. Mol. Cell Endocrinol. 365(1), 75\u201383 (2013).","journal-title":"Mol. Cell Endocrinol."},{"issue":"3","key":"87760_CR38","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1016\/j.autrev.2013.10.010","volume":"13","author":"A Antonelli","year":"2014","unstructured":"Antonelli, A. et al. Chemokine (C-X-C motif) ligand (CXCL)10 in autoimmune diseases. Autoimmun Rev. 13(3), 272\u2013280 (2014).","journal-title":"Autoimmun Rev."},{"issue":"7","key":"87760_CR39","doi-asserted-by":"crossref","first-page":"3602","DOI":"10.4049\/jimmunol.160.7.3602","volume":"160","author":"BR L\u00fadv\u00edksson","year":"1998","unstructured":"L\u00fadv\u00edksson, B. R. et al. Active Wegener\u2019s granulomatosis is associated with HLA-DR+ CD4+ T cells exhibiting an unbalanced Th1-type T cell cytokine pattern: reversal with IL-10. J. Immunol. 160(7), 3602\u20133609 (1998).","journal-title":"J. Immunol."},{"issue":"2","key":"87760_CR40","doi-asserted-by":"publisher","first-page":"266","DOI":"10.3390\/jcm8020266","volume":"8","author":"KS Lee","year":"2019","unstructured":"Lee, K. S. et al. Genetic variants in antineutrophil cytoplasmic antibody-associated vasculitis: a Bayesian approach and systematic review. J Clin Med 8(2), 266 (2019).","journal-title":"J Clin Med"},{"issue":"8","key":"87760_CR41","doi-asserted-by":"publisher","first-page":"1342","DOI":"10.1136\/annrheumdis-2012-201981","volume":"72","author":"PA Monach","year":"2013","unstructured":"Monach, P. A. et al. Serum proteins reflecting inflammation, injury and repair as biomarkers of disease activity in ANCA-associated vasculitis. Ann. Rheum. Dis. 72(8), 1342\u20131350 (2013).","journal-title":"Ann. Rheum. Dis."},{"issue":"3","key":"87760_CR42","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1056\/NEJMoa0909905","volume":"363","author":"JH Stone","year":"2010","unstructured":"Stone, J. H. et al. Rituximab versus cyclophosphamide for ANCA-associated vasculitis. N. Engl. J. Med. 363(3), 221\u2013232 (2010).","journal-title":"N. Engl. J. Med."},{"key":"87760_CR43","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1186\/s13075-015-0564-y","volume":"17","author":"TD de Jong","year":"2015","unstructured":"de Jong, T. D. et al. Effect of prednisone on type I interferon signature in rheumatoid arthritis: consequences for response prediction to rituximab. Arthritis Res. Ther. 17, 78 (2015).","journal-title":"Arthritis Res. Ther."},{"key":"87760_CR44","doi-asserted-by":"publisher","first-page":"m421","DOI":"10.1136\/bmj.m421","volume":"368","author":"ZS Wallace","year":"2020","unstructured":"Wallace, Z. S. & Miloslavsky, E. M. Management of ANCA associated vasculitis. BMJ 368, m421 (2020).","journal-title":"BMJ"},{"issue":"6","key":"87760_CR45","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1002\/jcla.21993","volume":"30","author":"A El-Gohary","year":"2016","unstructured":"El-Gohary, A. et al. Serum and urinary interferon-gamma-inducible protein 10 in lupus nephritis. J. Clin. Lab. Anal. 30(6), 1135\u20131138 (2016).","journal-title":"J. Clin. Lab. Anal."},{"key":"87760_CR46","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1186\/s13075-015-0773-4","volume":"17","author":"JH Han","year":"2015","unstructured":"Han, J. H. et al. Association of CXCL10 and CXCL13 levels with disease activity and cutaneous manifestation in active adult-onset Still\u2019s disease. Arthritis Res. Ther. 17, 260 (2015).","journal-title":"Arthritis Res. Ther."},{"issue":"11","key":"87760_CR47","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1080\/14767050701483298","volume":"20","author":"F Gotsch","year":"2007","unstructured":"Gotsch, F. et al. CXCL10\/IP-10: a missing link between inflammation and anti-angiogenesis in preeclampsia?. J. Matern. Fetal Neonatal Med. 20(11), 777\u2013792 (2007).","journal-title":"J. Matern. Fetal Neonatal Med."},{"issue":"11","key":"87760_CR48","doi-asserted-by":"publisher","first-page":"2761","DOI":"10.1093\/ndt\/gfh487","volume":"19","author":"FW Tam","year":"2004","unstructured":"Tam, F. W. et al. Urinary monocyte chemoattractant protein-1 (MCP-1) is a marker of active renal vasculitis. Nephrol. Dial. Transpl. 19(11), 2761\u20132768 (2004).","journal-title":"Nephrol. Dial. Transpl."},{"issue":"4","key":"87760_CR49","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1080\/09629350400003100","volume":"13","author":"S Ohlsson","year":"2004","unstructured":"Ohlsson, S., Wieslander, J. & Segelmark, M. Circulating cytokine profile in anti-neutrophilic cytoplasmatic autoantibody-associated vasculitis: prediction of outcome?. Mediators Inflamm. 13(4), 275\u2013283 (2004).","journal-title":"Mediators Inflamm."},{"key":"87760_CR50","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1186\/s13075-016-0978-1","volume":"18","author":"J Land","year":"2016","unstructured":"Land, J. et al. Regulatory and effector B cell cytokine production in patients with relapsing granulomatosis with polyangiitis. Arthritis Res. Ther. 18, 84 (2016).","journal-title":"Arthritis Res. Ther."},{"issue":"2","key":"87760_CR51","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1111\/j.1365-2249.2005.02770.x","volume":"140","author":"EA Torheim","year":"2005","unstructured":"Torheim, E. A. et al. Increased expression of chemokines in patients with Wegener\u2019s granulomatosis\u2014modulating effects of methylprednisolone in vitro. Clin. Exp. Immunol. 140(2), 376\u2013383 (2005).","journal-title":"Clin. Exp. Immunol."},{"issue":"7","key":"87760_CR52","doi-asserted-by":"publisher","first-page":"e2737","DOI":"10.1371\/journal.pone.0002737","volume":"3","author":"Y Yao","year":"2008","unstructured":"Yao, Y. et al. Type I interferon: potential therapeutic target for psoriasis?. PLoS ONE 3(7), e2737 (2008).","journal-title":"PLoS ONE"},{"issue":"2","key":"87760_CR53","doi-asserted-by":"publisher","first-page":"257","DOI":"10.3390\/biom10020257","volume":"10","author":"Y Romanova","year":"2020","unstructured":"Romanova, Y. et al. Proteomic analysis of human serum from patients with chronic kidney disease. Biomolecules 10(2), 257 (2020).","journal-title":"Biomolecules"},{"issue":"6","key":"87760_CR54","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1136\/ard.61.6.554","volume":"61","author":"C Vitali","year":"2002","unstructured":"Vitali, C. et al. Classification criteria for Sj\u00f6gren\u2019s syndrome: a revised version of the European criteria proposed by the American-European Consensus Group. Ann. Rheum. Dis. 61(6), 554\u2013558 (2002).","journal-title":"Ann. Rheum. Dis."},{"issue":"3","key":"87760_CR55","first-page":"69","volume":"24","author":"MM Mukaka","year":"2012","unstructured":"Mukaka, M. M. Statistics corner: a guide to appropriate use of correlation coefficient in medical research. Malawi Med. J. 24(3), 69\u201371 (2012).","journal-title":"Malawi Med. J."},{"issue":"3","key":"87760_CR56","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.tjem.2018.08.001","volume":"18","author":"H Akoglu","year":"2018","unstructured":"Akoglu, H. User\u2019s guide to correlation coefficients. Turk. J. Emerg. Med. 18(3), 91\u201393 (2018).","journal-title":"Turk. J. Emerg. Med."},{"issue":"7","key":"87760_CR57","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1038\/s41579-018-0020-5","volume":"16","author":"YC Perng","year":"2018","unstructured":"Perng, Y. C. & Lenschow, D. J. ISG15 in antiviral immunity and beyond. Nat. Rev. Microbiol. 16(7), 423\u2013439 (2018).","journal-title":"Nat. Rev. Microbiol."},{"issue":"1","key":"87760_CR58","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1089\/jir.2010.0110","volume":"31","author":"D Zhang","year":"2011","unstructured":"Zhang, D. & Zhang, D. E. Interferon-stimulated gene 15 and the protein ISGylation system. J. Interferon Cytokine Res. 31(1), 119\u2013130 (2011).","journal-title":"J. Interferon Cytokine Res."},{"issue":"7","key":"87760_CR59","doi-asserted-by":"publisher","first-page":"e0198325","DOI":"10.1371\/journal.pone.0198325","volume":"13","author":"Y Ding","year":"2018","unstructured":"Ding, Y. et al. Identification of a gene-expression predictor for diagnosis and personalized stratification of lupus patients. PLoS ONE 13(7), e0198325 (2018).","journal-title":"PLoS ONE"},{"key":"87760_CR60","doi-asserted-by":"publisher","unstructured":"Akiyama, H. et al. Interferon-inducible CD169\/Siglec1 attenuates anti-HIV-1 effects of alpha interferon. J. Virol. 91(21), e00972-17. https:\/\/doi.org\/10.1128\/JVI.00972-17 (2017).","DOI":"10.1128\/JVI.00972-17"},{"issue":"5","key":"87760_CR61","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1093\/bib\/bbr042","volume":"12","author":"P Gaudet","year":"2011","unstructured":"Gaudet, P. et al. Phylogenetic-based propagation of functional annotations within the Gene Ontology consortium. Brief. Bioinform. 12(5), 449\u2013462 (2011).","journal-title":"Brief. Bioinform."},{"issue":"1","key":"87760_CR62","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1089\/jir.2010.0127","volume":"31","author":"KA Fitzgerald","year":"2011","unstructured":"Fitzgerald, K. A. The interferon inducible gene: Viperin. J. Interferon Cytokine Res. 31(1), 131\u2013135 (2011).","journal-title":"J. Interferon Cytokine Res."},{"issue":"2","key":"87760_CR63","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1016\/j.chom.2007.06.009","volume":"2","author":"X Wang","year":"2007","unstructured":"Wang, X., Hinson, E. R. & Cresswell, P. The interferon-inducible protein viperin inhibits influenza virus release by perturbing lipid rafts. Cell Host Microbe 2(2), 96\u2013105 (2007).","journal-title":"Cell Host Microbe"},{"issue":"4","key":"87760_CR64","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1182\/blood-2012-01-407395","volume":"120","author":"N Nasr","year":"2012","unstructured":"Nasr, N. et al. HIV-1 infection of human macrophages directly induces viperin which inhibits viral production. Blood 120(4), 778\u2013788 (2012).","journal-title":"Blood"},{"issue":"4","key":"87760_CR65","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1038\/gene.2009.20","volume":"10","author":"ES Emamian","year":"2009","unstructured":"Emamian, E. S. et al. Peripheral blood gene expression profiling in Sj\u00f6gren\u2019s syndrome. Genes Immun. 10(4), 285\u2013296 (2009).","journal-title":"Genes Immun."},{"issue":"5","key":"87760_CR66","doi-asserted-by":"publisher","first-page":"3228","DOI":"10.1093\/nar\/gkt1321","volume":"42","author":"P Kumar","year":"2014","unstructured":"Kumar, P. et al. Inhibition of translation by IFIT family members is determined by their ability to interact selectively with the 5\u2032-terminal regions of cap0-, cap1- and 5\u2032ppp-mRNAs. Nucl. Acids Res. 42(5), 3228\u20133245 (2014).","journal-title":"Nucl. Acids Res."},{"issue":"5","key":"87760_CR67","doi-asserted-by":"publisher","first-page":"2462","DOI":"10.1128\/JVI.02744-14","volume":"89","author":"V Fensterl","year":"2015","unstructured":"Fensterl, V. & Sen, G. C. Interferon-induced Ifit proteins: their role in viral pathogenesis. J. Virol. 89(5), 2462\u20132468 (2015).","journal-title":"J. Virol."},{"issue":"1","key":"87760_CR68","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1186\/s12885-018-4529-9","volume":"18","author":"WC Huang","year":"2018","unstructured":"Huang, W. C. et al. IFI44L is a novel tumor suppressor in human hepatocellular carcinoma affecting cancer stemness, metastasis, and drug resistance via regulating met\/Src signaling pathway. BMC Cancer 18(1), 609 (2018).","journal-title":"BMC Cancer"},{"key":"87760_CR69","doi-asserted-by":"publisher","first-page":"e000995","DOI":"10.1136\/rmdopen-2019-000995","volume":"6","author":"A Bj\u00f6rk","year":"2020","unstructured":"Bj\u00f6rk, A. et al. Protein and DNA methylation-based scores as surrogate markers for interferon system activation in patients with primary Sj\u00f6gren\u2019s syndrome. RMD Open 6, e000995 (2020).","journal-title":"RMD Open"},{"issue":"23","key":"87760_CR70","doi-asserted-by":"publisher","first-page":"9373","DOI":"10.1073\/pnas.0903487106","volume":"106","author":"H Cheon","year":"2009","unstructured":"Cheon, H. & Stark, G. R. Unphosphorylated STAT1 prolongs the expression of interferon-induced immune regulatory genes. Proc. Natl. Acad. Sci. U. S. A. 106(23), 9373\u20139378 (2009).","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"6","key":"87760_CR71","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1089\/jir.2008.0027","volume":"29","author":"SL Deshmane","year":"2009","unstructured":"Deshmane, S. L. et al. Monocyte chemoattractant protein-1 (MCP-1): an overview. J. Interferon Cytokine Res. 29(6), 313\u2013326 (2009).","journal-title":"J. Interferon Cytokine Res."},{"issue":"8","key":"87760_CR72","doi-asserted-by":"publisher","first-page":"3623","DOI":"10.4049\/jimmunol.1401334","volume":"194","author":"E Cuadrado","year":"2015","unstructured":"Cuadrado, E. et al. Phenotypic variation in Aicardi-Gouti\u00e8res syndrome explained by cell-specific IFN-stimulated gene response and cytokine release. J. Immunol. 194(8), 3623\u20133633 (2015).","journal-title":"J. Immunol."},{"key":"87760_CR73","doi-asserted-by":"publisher","unstructured":"Blokland, S. L. M., Flessa, C. M., van Roon J. A. G. & Mavragani, C. P. Emerging roles for chemokines and cytokines as orchestrators of immunopathology in Sj\u00f6gren's syndrome. Rheumatology (Oxford) key438. https:\/\/doi.org\/10.1093\/rheumatology\/key438(2019).","DOI":"10.1093\/rheumatology\/key438"},{"issue":"6","key":"87760_CR74","first-page":"1006","volume":"34","author":"GM Balarini","year":"2016","unstructured":"Balarini, G. M. et al. Serum calprotectin is a biomarker of carotid atherosclerosis in patients with primary Sj\u00f6gren\u2019s syndrome. Clin. Exp. Rheumatol. 34(6), 1006\u20131012 (2016).","journal-title":"Clin. Exp. Rheumatol."},{"issue":"6","key":"87760_CR75","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1159\/000357780","volume":"21","author":"R Vazirinejad","year":"2014","unstructured":"Vazirinejad, R. et al. The biological functions, structure and sources of CXCL10 and its outstanding part in the pathophysiology of multiple sclerosis. NeuroImmunoModulation 21(6), 322\u2013330 (2014).","journal-title":"NeuroImmunoModulation"},{"key":"87760_CR76","doi-asserted-by":"publisher","first-page":"212","DOI":"10.3389\/fcell.2019.00212","volume":"7","author":"Y Yan","year":"2019","unstructured":"Yan, Y. et al. CCL19 and CCR7 expression, signaling pathways, and adjuvant functions in viral infection and prevention. Front. Cell Dev. Biol. 7, 212 (2019).","journal-title":"Front. Cell Dev. Biol."},{"issue":"1","key":"87760_CR77","doi-asserted-by":"publisher","first-page":"253","DOI":"10.4049\/jimmunol.178.1.253","volume":"178","author":"TE Pietil\u00e4","year":"2007","unstructured":"Pietil\u00e4, T. E. et al. Multiple NF-kappaB and IFN regulatory factor family transcription factors regulate CCL19 gene expression in human monocyte-derived dendritic cells. J. Immunol. 178(1), 253\u2013261 (2007).","journal-title":"J. Immunol."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-87760-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-87760-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-87760-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,2]],"date-time":"2023-11-02T04:24:37Z","timestamp":1698899077000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-87760-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4,15]]},"references-count":77,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,12]]}},"alternative-id":["87760"],"URL":"https:\/\/doi.org\/10.1038\/s41598-021-87760-4","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,4,15]]},"assertion":[{"value":"17 July 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 January 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 April 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"8272"}}